Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA targeting PLXND1
- Development stage
- Preclinical
- Lead developer
- University of California, Davis
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
siRNA targeting PLXND1 is an experimental RNA interference (RNAi) therapeutic approach designed to silence the expression of the PlexinD1 (PLXND1) receptor. PLXND1 is a semaphorin receptor that plays a critical role in cytoskeletal organization and cell adhesion. Research indicates that PLXND1 is significantly upregulated in neuroendocrine prostate cancer (NEPC), a highly aggressive and therapy-resistant form of prostate cancer that often arises through lineage plasticity. By utilizing siRNA to degrade PLXND1 mRNA, researchers have demonstrated reduced proliferation in NEPC cell lines and decreased viability in patient-derived xenograft (PDX) organoids. This suggests that targeting the PLXND1 pathway may provide a novel strategy for treating advanced prostate cancer and overcoming resistance to androgen receptor signaling inhibitors.
- Other names
- PLXND1 siRNAPLXND-1 siRNAPLXND 1 siRNAPlexinD1 siRNAPlexinD-1 siRNAPlexinD 1 siRNA
02
Targets
PLXND1
Beyond the preview
Go deeper on siRNA targeting PLXND1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA targeting PLXND1.